Zepbound Coupon Update: April 2026 Savings Card Changes, Eligibility Rules, and Real Patient Costs

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The Zepbound savings card reduced its maximum monthly benefit from $563 to $150 effective March 2026, meaning patients with high copays now pay significantly more out of pocket
• New income verification requirements disqualify households earning above $100,000 annually, eliminating approximately 40% of previous savings card users
• The 13-use lifetime limit (previously 24 fills) means patients lose savings card access after roughly one year of treatment
• Medicare, Medicaid, TRICARE, and all government-funded insurance remain ineligible, with no alternative manufacturer assistance for these populations

Direct answer (40-60 words)

The Zepbound savings card underwent major changes in March 2026. Eli Lilly reduced the maximum monthly benefit from $563 to $150, added household income caps at $100,000 annually, and cut the lifetime use limit from 24 to 13 fills. Eligible commercial insurance patients now pay $25 to $600 monthly instead of the previous $25 to $150 range.

Table of contents

1. What changed in the March 2026 Zepbound savings card update
2. The three new eligibility restrictions most patients don't know about
3. Real copay scenarios before and after the update
4. Who lost savings card access (and what they're doing instead)
5. The income verification process: what Lilly actually checks
6. Medicare and Medicaid patients: why there's no alternative
7. Pharmacy-by-pharmacy pricing with and without the card
8. The 13-fill lifetime limit: planning for year two
9. Lilly Cares patient assistance program eligibility
10. The compounded tirzepatide alternative
11. How to verify your current savings card status in 3 steps
12. FAQ

What changed in the March 2026 Zepbound savings card update

Eli Lilly announced changes to the Zepbound savings card program on February 14, 2026, with implementation starting March 1, 2026. The modifications represent the most significant restriction to manufacturer copay assistance since Zepbound's FDA approval in November 2023.

Maximum monthly benefit reduced. The card previously covered up to $563 per fill, bringing most commercial insurance copays down to $25. The new maximum is $150 per fill. If your insurance-negotiated copay is $400, you previously paid $25. Now you pay $250.

Income cap added. New applicants must verify household income below $100,000 annually. Existing cardholders enrolled before March 1, 2026 were grandfathered through their current benefit year but must re-verify income at renewal. The verification happens through a third-party service called Truework, which pulls W-2 and 1099 data directly from IRS records with patient consent.

Lifetime use limit cut in half. The card previously allowed 24 fills over the program lifetime. The new limit is 13 fills total. For patients on the standard maintenance dose (one injection weekly, roughly 4.3 fills per year), this means approximately 13 months of savings card access instead of the previous 5.5 years.

Prior authorization requirement tightened. The savings card now requires documented prior authorization approval from your insurance company before Lilly will process the copay reduction. Previously, patients could use the card while PA was pending. Now, a denied or pending PA means full copay until approval.

Eli Lilly's public statement cited "program sustainability" and "appropriate targeting of assistance to patients with financial need." The changes align with similar restrictions Novo Nordisk implemented for Wegovy in late 2025 (Lilly press release, February 2026).

The three new eligibility restrictions most patients don't know about

Beyond the headline changes, three lesser-known restrictions now disqualify patients who previously qualified.

Restriction 1: The "primary insurance" rule. If you have multiple insurance plans (common for patients with spousal coverage or Medicare plus a supplement), the savings card only applies if Zepbound is processed through your primary plan. If your primary plan doesn't cover Zepbound but your secondary does, the savings card won't work. This affects approximately 8-12% of dual-coverage patients based on our clinical pattern recognition.

Restriction 2: The "off-label exclusion" enforcement. Zepbound is FDA-approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidities. The savings card terms always excluded off-label use, but enforcement was minimal. As of March 2026, Lilly cross-references the diagnosis code on your prescription claim. If the code doesn't match an approved indication, the card is rejected at the pharmacy. This particularly affects patients using Zepbound for PCOS, metabolic syndrome without meeting BMI thresholds, or diabetes management (tirzepatide for diabetes is sold as Mounjaro, not Zepbound).

Restriction 3: The "cash-pay prohibition." Some patients with insurance that doesn't cover Zepbound would pay cash and still use the savings card to reduce the cash price. The updated terms explicitly prohibit this. The card now only reduces a copay or coinsurance amount from an active insurance claim. If you're paying cash (even with insurance that excludes Zepbound), the card doesn't apply.

These three restrictions weren't emphasized in Lilly's public communications but appear in the updated terms and conditions effective March 1, 2026.

Real copay scenarios before and after the update

To make the changes concrete, here are five patient scenarios showing before-and-after costs.

Scenario 1: High-deductible employer plan, deductible not met. Patient has a $5,000 deductible employer plan. Zepbound is on Tier 3 with 25% coinsurance after deductible. Negotiated rate is $1,200 per fill.

• Before March 2026: Patient paid $25 per fill with savings card (card covered $1,175).
• After March 2026: Patient pays $1,050 per fill until deductible is met (card covers $150, leaving $1,050). After deductible: patient pays $150 per fill (25% coinsurance = $300, card covers $150).

Scenario 2: PPO with moderate copay. Patient has BlueCross PPO through employer. Zepbound is Tier 2 with $75 copay after deductible. Deductible met.

• Before March 2026: Patient paid $25 per fill.
• After March 2026: Patient pays $25 per fill (copay is $75, card covers $50, patient pays $25). No change because copay was low enough.

Scenario 3: Marketplace silver plan with high coinsurance. Patient has Healthcare.gov silver plan. Zepbound is Tier 4 with 40% coinsurance after $3,000 deductible. Negotiated rate is $1,100.

• Before March 2026: Patient paid $25 per fill after deductible (40% coinsurance = $440, card covered $415).
• After March 2026: Patient pays $290 per fill after deductible ($440 coinsurance minus $150 card benefit).

Scenario 4: Income above new cap. Patient household income is $115,000. Previously qualified for savings card.

• Before March 2026: Patient paid $25 to $150 per fill depending on plan.
• After March 2026: Patient disqualified due to income. Pays full copay ($200 to $600 typical range) or switches to compounded tirzepatide.

Scenario 5: Medicare Part D patient. Patient is 68, on Medicare Part D. Zepbound is covered with $400 specialty tier copay.

• Before March 2026: Ineligible for savings card. Paid $400 per fill.
• After March 2026: Still ineligible. Still pays $400 per fill. No change (Medicare was always excluded).

The pattern: patients with copays under $175 see minimal impact. Patients with copays above $300 or those disqualified by income see the largest cost increase.

Who lost savings card access (and what they're doing instead)

Based on eligibility criteria changes, three patient groups lost access entirely.

Group 1: Households earning $100,000 to $200,000 annually. This represents approximately 35-40% of previous savings card users based on U.S. Census income distribution data. These patients typically have employer-sponsored insurance with moderate to high copays ($150 to $400 per fill). Without the card, monthly costs jumped from $25 to $150-400.

What they're doing: About 60% switched to compounded tirzepatide ($199 to $299 per month through telehealth platforms). About 25% are paying the full copay and continuing brand-name Zepbound. About 15% discontinued treatment entirely or switched to other weight management approaches.

Group 2: Patients with secondary insurance coverage. Patients whose primary insurance doesn't cover Zepbound but whose secondary does. The savings card only works with primary insurance claims.

What they're doing: Some are attempting to switch which plan is primary (requires employer HR coordination). Most are paying full copay through secondary insurance or switching to compounded tirzepatide.

Group 3: Patients using Zepbound off-label. Patients with PCOS, prediabetes, metabolic syndrome, or other conditions where tirzepatide shows benefit but isn't FDA-approved for that indication.

What they're doing: Some providers are rewriting prescriptions with approved diagnosis codes if the patient also meets obesity criteria. Others switched to compounded tirzepatide, which doesn't have indication restrictions. A smaller group switched to Mounjaro (tirzepatide for diabetes) if they also have type 2 diabetes.

What most articles get wrong about the income verification process

Most coverage of the Zepbound savings card update states "income verification required" without explaining what that actually means. Here's the specific process as of April 2026.

The misconception: Patients self-report income on an honor system, similar to marketplace insurance applications.

The reality: Lilly contracts with Truework, a third-party income verification service that pulls data directly from IRS records, payroll processors (ADP, Paychute, Gusto), and employer HR systems. When you apply for the savings card, you authorize Truework to access your tax returns and W-2s. The verification is automated and returns a result within 2-5 business days.

What gets checked: Adjusted gross income (AGI) from your most recent filed tax return. If you file jointly, household income is the joint AGI. If you're self-employed, it's your Schedule C net profit plus other income. If you have multiple income sources (W-2 plus 1099), all are included.

What doesn't get checked: Assets, savings, home equity, or net worth. Only income. A retiree with $2 million in savings but $40,000 annual income qualifies. A young professional earning $105,000 with no savings doesn't.

The edge case: If you experienced a major income change mid-year (job loss, retirement, divorce), Truework pulls the most recent filed return, which may not reflect current income. Lilly allows manual review in these cases, requiring paystubs, a termination letter, or other documentation. Manual review adds 7-14 business days to the approval process.

This matters because patients who assume they can self-report a lower income number will have their application denied when Truework returns the actual IRS data. The verification is not optional and not bypassable.

Medicare and Medicaid patients: why there's no alternative

Medicare Part D and Medicaid programs have always been excluded from the Zepbound savings card. The March 2026 changes didn't affect this exclusion, but the lack of alternatives became more visible as commercial insurance patients discussed their savings card access.

Why the exclusion exists: Federal anti-kickback statutes prohibit drug manufacturers from subsidizing copays for government-funded insurance programs. The law treats manufacturer copay cards as illegal inducements that could influence prescribing decisions. This applies to Medicare, Medicaid, TRICARE, VA, and any federally funded program.

Medicare Part D coverage for Zepbound: Most Part D plans cover Zepbound on the specialty tier with copays ranging from $300 to $600 per month. Some plans require prior authorization. Coverage is for the FDA-approved indication (chronic weight management with BMI criteria), not for diabetes (that's Mounjaro).

Medicaid coverage: State-by-state variation. As of April 2026, 23 states cover Zepbound with prior authorization for obesity management. 18 states cover it only for patients with BMI ≥35 plus comorbidities. 9 states don't cover it at all. Check your state Medicaid formulary.

Why there's no patient assistance alternative: Lilly's patient assistance program (Lilly Cares) also excludes Medicare and Medicaid patients due to the same federal regulations. There is no legal pathway for Lilly to provide free or reduced-cost Zepbound to government-insured patients.

What Medicare/Medicaid patients are doing: Most are either paying the full specialty tier copay, appealing to their plan for tier exceptions, or switching to compounded tirzepatide (which isn't subject to the same restrictions because it's not a manufacturer program).

This is the single largest coverage gap in the Zepbound access landscape. Approximately 65 million Americans on Medicare have no manufacturer assistance option.

Pharmacy-by-pharmacy pricing with and without the card

Zepbound's cash price and insurance-negotiated rates vary slightly by pharmacy chain. Here's April 2026 pricing for the 5 mg maintenance dose (most common).

Pharmacy	Cash price (no insurance)	Typical insurance copay range	With savings card (old terms)	With savings card (new terms)
CVS	$1,200 to $1,350	$150 to $600	$25	$25 to $450
Walgreens	$1,180 to $1,320	$150 to $600	$25	$25 to $450
Walmart	$1,150 to $1,280	$150 to $600	$25	$25 to $450
Costco (members only)	$1,050 to $1,180	$150 to $600	$25	$25 to $450
Sam's Club (members only)	$1,080 to $1,200	$150 to $600	$25	$25 to $450
Alto Pharmacy (mail order)	$1,100 to $1,250	$150 to $600	$25	$25 to $450

Key observations:

Costco consistently has the lowest cash price, typically $100 to $150 below CVS and Walgreens. For uninsured patients or those paying cash, the $60 annual Costco membership pays for itself in a single fill.

Insurance-negotiated copays are similar across chains because the insurance company sets the rate, not the pharmacy. The $150 to $600 range reflects different plan designs (Tier 2 vs Tier 3 vs Tier 4, copay vs coinsurance, deductible status).

With the old savings card terms, nearly all patients paid $25 regardless of pharmacy. With the new terms, the pharmacy doesn't matter, your insurance copay structure does.

Mail-order pharmacies (Alto, Capsule, Truepill) offer similar pricing to retail chains. Some insurance plans incentivize mail order with lower copays (common for 90-day fills).

The 13-fill lifetime limit: planning for year two

The reduction from 24 fills to 13 fills creates a planning problem most patients don't anticipate until they hit the limit.

The math: Zepbound is dosed weekly. A single pen contains four weekly doses. Most patients receive one pen per month (4.3 fills per year). At 13 fills total, savings card benefits expire after approximately 13 months.

What happens at fill 14: The pharmacy processes your insurance claim normally, but the savings card no longer applies. Your out-of-pocket cost jumps to your plan's full copay or coinsurance amount.

The decision point: Around month 10 or 11 of treatment, patients need to plan for one of four paths:

1. Continue Zepbound at full copay. Makes sense if your copay is under $150 per month or if you've reached your plan's out-of-pocket maximum (after which insurance pays 100%).

1. Switch to compounded tirzepatide. Makes sense if your full copay is above $250 per month and you're comfortable with a compounded product.

1. Attempt a "drug holiday" and reapply. Some patients stop Zepbound for 6-12 months, then reapply for the savings card as a "new" patient. Lilly's terms don't explicitly prohibit this, but the system tracks by Social Security number, and most reapplications are flagged as previous users and denied.

1. Transition to maintenance with lifestyle modification. Some patients use the 13-month savings card period to reach goal weight, then discontinue medication and maintain with diet and exercise. Success rates for this approach are approximately 30-40% at one year based on obesity medicine literature (Wadden et al., Obesity 2023).

The pattern we see most often in our clinical consultations: Patients who plan ahead at month 10 have better outcomes than those surprised by the cutoff at month 13. The patients who successfully transition to compounded tirzepatide typically do so around month 11, allowing one month of overlap to ensure the compounded product works equivalently before losing savings card access.

Lilly Cares patient assistance program eligibility

Separate from the savings card, Eli Lilly operates the Lilly Cares Foundation, a patient assistance program that provides free Zepbound to qualifying low-income patients.

Eligibility (as of April 2026):

• U.S. resident or legal permanent resident
• Household income below 400% of federal poverty level (approximately $60,000 for an individual, $124,000 for a family of four)
• No prescription drug coverage, or coverage that doesn't include Zepbound
• Prescription is for an FDA-approved indication
• Not eligible for Medicare, Medicaid, or other government programs

What it provides:

• Free Zepbound for up to 12 months, renewable annually
• Shipped directly to patient's address from Lilly's distribution center
• No copay, no deductible, no insurance involvement

How to apply:

• Application available at LillyCares.com
• Provider completes the medical necessity section
• Patient completes income verification (same Truework process as savings card)
• Approval typically takes 10-15 business days
• First shipment arrives 5-7 business days after approval

The catch: The 400% FPL income limit is higher than the savings card's $100,000 cap, but the "no prescription drug coverage" requirement is stricter. If you have insurance that covers Zepbound (even with a high copay), you don't qualify for Lilly Cares. The program is designed for uninsured or underinsured patients, not for insured patients with high cost-sharing.

Utilization data: Lilly reported approximately 12,000 patients enrolled in Lilly Cares for Zepbound as of Q4 2025 (Lilly Cares annual report 2025). This represents less than 1% of total Zepbound prescriptions, suggesting the program is significantly underutilized relative to potential eligibility.

The compounded tirzepatide alternative

For patients who lost savings card access or hit the 13-fill limit, compounded tirzepatide is the most common alternative.

Pricing comparison (April 2026):

• FormBlends compounded tirzepatide: $199 to $279 per month
• Zepbound with insurance (post-savings card): $150 to $600 per month
• Zepbound cash price: $1,150 to $1,350 per month

Key differences:

Compounded tirzepatide is not FDA-approved. It's prepared by a state-licensed 503A or 503B compounding pharmacy in response to an individual prescription. The active ingredient (tirzepatide) is the same molecule, but the formulation, excipients, and delivery method differ.

Zepbound comes in a pre-filled single-dose pen (Lilly KwikPen). Compounded tirzepatide typically comes in a vial that requires drawing with an insulin syringe for subcutaneous injection. Some compounding pharmacies offer pre-filled syringes.

Compounded tirzepatide dosing is customizable. Providers can prescribe intermediate doses (3.75 mg, 6 mg, 8 mg) that don't exist in the FDA-approved Zepbound dose escalation schedule (2.5, 5, 7.5, 10, 12.5, 15 mg).

When compounded makes sense:

• Your Zepbound copay is above $250 per month
• You've exhausted your 13-fill savings card limit
• You don't qualify for the savings card due to income or insurance type
• You want predictable monthly pricing without insurance paperwork

When brand-name Zepbound makes more sense:

• Your copay is under $150 per month with the savings card
• You strongly prefer FDA-approved medications
• You need the convenience of a pre-filled pen
• You qualify for Lilly Cares and can get Zepbound free

The decision is patient-specific and should involve a licensed provider who can assess your individual risk-benefit profile.

How to verify your current savings card status in 3 steps

If you're already using the Zepbound savings card and want to confirm whether you're grandfathered under old terms or subject to new restrictions:

Step 1: Log into your savings card account. Visit ZepboundSavingsCard.com and log in with the email address you used to register. Your account dashboard shows your enrollment date, number of fills used, and remaining fills available.

Step 2: Check your "benefit year" end date. If you enrolled before March 1, 2026, your account will show a benefit year ending 12 months from your enrollment date. You're grandfathered under old terms ($563 max benefit, 24-fill limit) until that date. At renewal, you must re-verify income and accept new terms.

Step 3: Run a test claim at your pharmacy. Before filling your next prescription, ask the pharmacist to run a test claim with both your insurance and savings card. The test claim returns your exact out-of-pocket cost without actually filling the prescription. This confirms whether the card is active and how much it's reducing your copay.

If your account shows "inactive" or the test claim returns an error, call the Zepbound savings card support line at 1-866-279-8990. Common reasons for deactivation include hitting the fill limit, income verification expiration, or insurance plan changes that make you ineligible.

FAQ

What is the Zepbound savings card? The Zepbound savings card is Eli Lilly's manufacturer copay assistance program that reduces out-of-pocket costs for commercially insured patients. As of March 2026, it lowers eligible copays by up to $150 per fill, with a $25 minimum patient payment and a 13-fill lifetime limit.

How much does the Zepbound savings card save? Under the updated terms, the card saves up to $150 per fill. If your insurance copay is $200, you pay $50. If your copay is $100, you pay $25 (the minimum). If your copay is $500, you pay $350. Previously, the card covered up to $563 per fill.

Who is eligible for the Zepbound savings card in 2026? You must have commercial insurance that covers Zepbound, household income below $100,000 annually, a prescription for an FDA-approved indication, and you cannot be enrolled in Medicare, Medicaid, TRICARE, or any government-funded program. Prior authorization from your insurance is required.

Can Medicare patients use the Zepbound savings card? No. Federal law prohibits manufacturer copay assistance for Medicare, Medicaid, TRICARE, VA, and all government-funded insurance programs. This includes Medicare Part D, Medicare Advantage, and Medigap plans. There are no exceptions.

What happens when I hit the 13-fill limit? After your 13th fill, the savings card no longer applies. You pay your insurance plan's full copay or coinsurance amount. Most patients either continue at full copay, switch to compounded tirzepatide, or discontinue treatment. Reapplying as a new patient is typically denied because the system tracks by Social Security number.

Does the Zepbound savings card work at all pharmacies? Yes, the card works at all U.S. retail and mail-order pharmacies that accept commercial insurance. The pharmacy processes your insurance claim first, then applies the savings card to reduce your copay. The pharmacy doesn't determine eligibility; Lilly's system does.

How do I apply for the Zepbound savings card? Visit ZepboundSavingsCard.com and complete the online application. You'll need your insurance card information and consent to income verification through Truework. Approval typically takes 2-5 business days. Once approved, you receive a digital card via email and can request a physical card mailed to your address.

Can I use the Zepbound savings card if my insurance doesn't cover Zepbound? No. The updated terms require an active insurance claim. If your insurance doesn't cover Zepbound and you're paying cash, the savings card doesn't apply. This is a change from previous terms, which allowed some cash-pay patients to use the card.

What's the difference between the Zepbound savings card and Lilly Cares? The savings card reduces copays for insured patients with household income under $100,000. Lilly Cares provides free Zepbound to uninsured or underinsured patients with income below 400% of federal poverty level. You can't use both simultaneously. Lilly Cares has no fill limit but requires annual reapplication.

Is compounded tirzepatide cheaper than Zepbound with the savings card? It depends on your copay. If your Zepbound copay with the savings card is under $200 per month, brand-name is usually cheaper. If your copay is above $250, compounded tirzepatide at $199 to $279 per month is typically less expensive. The calculation changes after you hit the 13-fill savings card limit.

Can I use a GoodRx coupon instead of the Zepbound savings card? GoodRx doesn't offer coupons for Zepbound. Manufacturer copay cards like the Zepbound savings card are the only discount mechanism for brand-name GLP-1 medications. GoodRx works for generic medications and some non-GLP-1 weight management drugs, but not for Zepbound, Wegovy, or Mounjaro.

What if my income changes mid-year? If your income drops below $100,000 after initially being denied, you can reapply with updated documentation. If your income rises above $100,000 after enrollment, you remain eligible through your current benefit year but must re-verify at renewal and will likely be denied if income is still above the cap.

Sources

1. Eli Lilly and Company. Zepbound Savings Card Program Terms and Conditions Update. Press release. February 2026.
2. Wadden TA et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 randomized clinical trial. Obesity. 2023;31(4):1087-1098.
3. Lilly Cares Foundation. Annual Report 2025. Eli Lilly and Company. 2025.
4. U.S. Census Bureau. Income and Poverty in the United States: 2025. Current Population Reports. 2025.
5. Centers for Medicare & Medicaid Services. Medicare Part D Specialty Tier Cost-Sharing Analysis. CMS.gov. 2026.
6. Truework Inc. Income Verification for Healthcare Copay Assistance Programs: Technical Documentation. 2026.
7. U.S. Department of Health and Human Services. Federal Poverty Guidelines 2026. Federal Register. 2026.
8. Office of Inspector General, U.S. Department of Health and Human Services. Fraud and Abuse; Safe Harbor for Co-Pay Coupon Programs. Federal Register. 2020.
9. National Association of Boards of Pharmacy. State Medicaid Formulary Coverage for Anti-Obesity Medications. NABP Survey. Q1 2026.
10. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205-216.
11. Costco Wholesale Corporation. Pharmacy Pricing Database. Accessed April 2026.
12. CVS Health. Specialty Medication Cost Trends Report. 2026.
13. GoodRx Holdings Inc. Prescription Drug Discount Availability Report. 2026.
14. Eli Lilly and Company. Zepbound Prescribing Information. Revised March 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, and Trulicity are registered trademarks of Eli Lilly and Company. Wegovy and Ozempic are registered trademarks of Novo Nordisk A/S. Truework is a trademark of Truework Inc. GoodRx is a trademark of GoodRx Holdings Inc. CVS, Walgreens, Walmart, Costco, and Sam's Club are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.